Congenital Hypotonia | Stem Cell Treatment | My Story
Saif and his mother, like many other families, were left with no hope after Saif was diagnosed with Benign Congenital Hypotonia, a muscle weakness disease similar to Muscular Dystrophy. Local...
By: Repair Stem Cells
More here:
Congenital Hypotonia | Stem Cell Treatment | My Story - Video
Tampa, FL (PRWEB) September 04, 2014
On Tuesday, September 9, the Lung Institute will hold an inaugural Stem Cell Social at its Tampa location. The Lung Institute created this event to address how stem cell treatment can help lung disease sufferers. Attendees will have the opportunity to learn how stem cell therapy can help, as well as set up a free consultation. In addition, a number of recent patients will be present to share how stem cell therapy has personally impacted their lives by repairing damaged lung tissue and improving function.
As a leader in regenerative medicine, the Lung Institute has provided almost 300 stem cell treatments to lung disease patients who previously had no hope for better breathing and regaining quality of life. The Lung Institute treats lung diseases including pulmonary fibrosis and chronic obstructive pulmonary disease (COPD), a progressive disease that causes difficulty breathing, and is the third leading cause of death in the United States.
Led by Dr. Burton Feinerman, a world-renowned physician in the field of regenerative medicine, the Lung Institute offers minimally invasive, and outpatient stem cell treatments for patients with a variety of debilitating lung diseases. Stem cells are taken from the patients own blood or fat tissue. The treatments cue healing processes in the lungs, allowing patients to get back to normal, everyday activities and breathe easier.
Patients from the United States and around the world have traveled to Tampa to receive treatment. We provide hope to our patients, and an improved quality of life, said Dr. Feinerman. Our inaugural stem cell social is the perfect opportunity to learn about this innovative treatment option that can literally change a persons life.
Join the Lung Institute for its inaugural Stem Cell Social:
When: Tuesday, September 9, 4 p.m.7 p.m. Where: Lung Institute, 201 E. Kennedy Blvd., Suite 425, Tampa, FL 33602 What: A presentation by Dr. Feinerman and feedback from his patients about stem cell therapy. In addition, there will be refreshments and three grand-prize winners will receive $3,000 gift cards toward the purchase of treatment at the Lung Institute*! RSVP: Space is limited with only 30 spots available. Please RSVP to (855) 469-5864.
About the Lung Institute At the Lung Institute, we are changing the lives of hundreds of people across the nation through the innovative technology of regenerative medicine. We are committed to providing patients a more effective way to address pulmonary conditions and improve quality of life. Our physicians, through their designated practices, have gained worldwide recognition for the successful application of revolutionary minimally invasive stem cell therapies. With over a century of combined medical experience, our doctors have established a patient experience designed with the highest concern for patient safety and quality of care. For more information, visit our website at LungInstitute.com, like us on Facebook, follow us on Twitter or call us today at (855) 469-5864.
Read more from the original source:
Lung Institute Holds Inaugural Stem Cell Social
The treatment involves injecting up to 20 million stem cells into patients' brains. It was tested on patients at Glasgow's Southern General Hospital in 2012.
The Surrey-based company said it would work at 10 sites across the UK, including the Southern General, on a Phase II efficacy study of the ReN001 treatment involving 41 patients.
Loading article content
The treatment is designed to deliver a meaningful improvement in upper limb function in disabled stroke patients.
In May, the company said data from a long-term follow- up involving 11 patients included in a Phase I safety study of ReN001 at the Glasgow hospital observed sustained reductions in neurological impairment and spasticity in most patients. No cell-related or immunological adverse events were reported .
Yesterday, Reneuron said it has also started a Phase I safety study at Ninewells Hospital in Dundee of its ReN009 therapy for people with lower limb ischaemia. It will involve nine patients.
Reneuron says the disease is common in patients with diabetes and can lead to amputation of the limb.
Follow this link:
Reneuron tests stem cell stroke treatment
Los Angeles, California (PRWEB) September 03, 2014
Stem Cell technology is the future; looking younger and better without plastic surgery is here now. Stem Cell Beautys debut product line StemLife is spearheading the current beauty renaissance. Among websites that provide stem cell beauty products, Stem Cell Beauty is in a league of its own.
Science is always advancing, why shouldn't your beauty products? questions Albert Faleski, Director of Operations at StemCellBeauty.com.
Most products on the shelves are outdated, whereas we take a different approach to find a formula that works with your body, reinvigorating your own stem cells to provide actual results.
The science behind StemLife is nothing short of groundbreaking. Its trademarked FixT Technology was achieved through reverse engineering to understand how the body maintains and heals itself with our own endogenous combinations of adult stem cells. With this knowledge they developed a means to mimic the natural stem cell processes in our body. Unlike other beauty brands, StemLife uses specific combinations of stem cell types, each cultured under specific state-dependent conditions, using cell types and states that are ideal for the particular tissue. It then creates a set of molecules from multiple stem cell types that is complete and fully formed, rendering maximum benefit and efficiency. This approach of stem cell skin care is extremely unique.
Other leading stem cell-based beauty companies use simpler technology where one stem cell type is chosen to make their molecules. This one-size fits all approach is not efficient and lacks the complexity of StemLifes FixT technology. Some companies mash the cells without allowing their molecules to fully process, which again leads to underachieving results. Many of the largest companies have made no attempt to use new science to formulate better products, providing their customers with over-priced serums proven to be archaic.
StemLifes cutting edge formula is shaping the future of hair regrowth as well, providing an ultramodern solution to those looking to slow the hands of time. Their most popular product, The Advanced Hair Treatment for Women, is essentially the hidden gem the world has been waiting for.
Its popularity stems back to the fact that it actually works. Faleski explained.
Were not big on gimmicks. We prefer showing our customer actual people who have had actual results with our products. After seeing life-changing hair growth with their own eyes, we are confident new customers will try it and have amazing results of their own. The Advanced Hair Treatment for Women is an incredible product that sells itself.
StemLifes most interesting product to date is the Natural Lash & Brow Lash Extend. This product boasts ingredients that are formulated to generate eyelash growth. In a market where eyelash extensions have been the go-to fix for longer lashes, being able to naturally grow them is a revolutionary concept.
See original here:
Stem Cell Beauty: The Online Shop Revolutionizing the Beauty Industry
La Jolla, CA (PRWEB) September 03, 2014
A new study, published on Aug. 8th, 2014 in Stem Cells Translational Medicine, has shown the positive effect stem cell therapy has had on a group of patients only 6 months after their treatment. Researchers observed significant improvements in disease-related complications in each of the 5 patients included in the study. Post-treatment brain scans of each patient revealed that stroke-related damage was reduced over time. Further, at six-month follow-ups patients demonstrated improvements in standard measures of stroke-related disability and impairment.
Researchers are being cautiously optimistic when considering these results. Similar improvements are often seen in stroke patients as part of the normal recovery process and state that more thorough studies will need to be completed. Nonetheless, the findings are absolutely astounding as the five patients included in this study suffered severe strokes. Four out of five of the patients had the most serious type of stroke. Normally only 4% of these patients survive and are able to live independently after six months of a stroke occurrence.
Clinical studies for stem cell treatment are currently being offered by StemGenex to patients diagnosed with Stroke and other degenerative neurological diseases. Innovation is truly a driving force for StemGenex. Stroke Patients who receive stem cell treatment through StemGenex receive multiple therapeutic modalities they simply cannot find elsewhere under one roof, said Jeremiah McDole, Director of Scientific Research and Development at StemGenex. Offering targeted therapies that deliver stem cells past the blood brain barrier is essential to providing effective treatment for patients with neurological disorders.
StemGenex takes a unique approach of compassion and empowerment while providing access to the latest stem cell therapies for degenerative neurological diseases including Multiple Sclerosis, Parkinsons Alzheimers disease, and others. Rita Alexander, founder of StemGenex and the companys first stem cell patient, insists that all patients be treated like they are one of our loved ones. Hope, compassion, and the relentless pursuit for an end to these diseases are the primary focus.
To find out more about stem cell therapy, contact StemGenex either by phone at (800) 609-7795 or email Contact@stemgenex.com
Read more from the original source:
Latest Study on Stem Cell Therapy Shows Promising Signs of Recovery for Stroke Patients and Support for StemGenex ...
PUBLIC RELEASE DATE:
3-Sep-2014
Contact: Robert Miranda cogcomm@aol.com Cell Transplantation Center of Excellence for Aging and Brain Repair
Putnam Valley, NY. (Sept. 3, 2014) A team of researchers from Korea and Canada have found that transplantation of B10 cells (a stable immortalized human bone marrow derived mesenchymal stem cell line; B10 hMSC) directly into the bladder wall of mice modeled with spinal cord injury (SCI) helped inhibit the development of bladder fibrosis and improved bladder function by promoting the growth of smooth muscle cells in the bladder.
The study will be published in a future issue of Cell Transplantation and is currently freely available on-line as an unedited early e-pub at: http://www.ingentaconnect.com/content/cog/ct/pre-prints/content-CT-1227_Lee.
Spinal cord injury (SCI) can cause severe lower urinary tract dysfunction and conditions such as overactive bladder, urinary retention and increased bladder thickness and fibrosis. HMSCs, multipotent cells that can differentiate into a variety of cell types, including bone cells, cartilage cells, and fat cells, have been transplanted into injured spinal cords to help patients regain motor function.
In this study, mice receiving the B10 hMSCs injected directly into the bladder wall experienced improved bladder function while an untreated control group did not.
"Human MSCs can secrete growth factors," said study co-author Seung U. Kim of the Division of Neurology at the University of British Columbia Hospital, Vancouver, Canada. "In a previous study, we showed that B 10 cells secrete various growth factors including hepatocyte growth factor (HGF) and that HGF inhibits collagen deposits in bladder outlet obstructions in rats more than hMSCs alone. In this study, the SCI control group that did not receive B10 cells showed degenerated spinal neurons and did not recover. The B10-injected group appeared to have regenerated bladder smooth muscle cells."
Four weeks after the onset of SCI, the treatment group received the B10 cells transplanted directly into the bladder wall. To track the transplanted B10 cells via magnetic resonance imaging (MRI), the researchers labeled them with fluorescent magnetic particles.
"HGF plays an essential role in tissue regeneration and angiogenesis and acts as a potent antifibrotic agent," explained Kim.
Here is the original post:
Transplanted stem cells help prevent bladder fibrosis after spinal cord injury
Richfeel: Have a great hair day
Dr. Apoorva Shah Dr. Sonal Shah, India #39;s leading trichologists and founder of Richfeel Hair and Scalp Clinic, talk about Hair fall Hair prevention. Also, explaining about plant stem-cell...
By: Richfeel Trichology
Read more:
Richfeel: Have a great hair day - Video
KYOTO: Prime Minister Narendra Modi Sunday discussed cooperation with Japan to combat sickle cell anaemia that is prevalent in India's tribal regions, an official said.
Modi met Shinya Yamanaka, Japan's stem cell pioneer and 2012 Nobel Prize winner, at Kyoto University and discussed treatment of the disease.
They discussed the "possibilities of sickle cell anaemia cure" and "prospects of cooperation among Indian and Japanese institutes", tweeted an external affairs ministry spokesman.
"The prime minister expressed concern over the prevalence of sickle cell anaemia, especially among tribal communities across India," a statement by the Indian government said.
Sickling decreases the cells' flexibility and results in a risk of various life threatening complications. It mostly occurs in regions where malaria is rampant.
"The prime minister urged Yamanaka to work towards a cure for this," the statement said.
Yamanaka said there were currently no Indian researchers at his institute, the Centre for iPS Cell Research and Application, and "he would like Indian scientists to conduct research at the institute".
Stay updated on the go with The Times of Indias mobile apps. Click here to download it for your device.
Go here to read the rest:
PM Modi meets Nobel prize winner Yamanaka, discusses treatment of sickle cell anaemia remedy
Modi talks with Nobel Laureate Prof Yamanaka about treatment of sickle cell anaemia. Photograph: MEA/Facebook
Japan on Sunday agreed to work with India in developing a treatment for the sickle cell anaemia after Prime Minister Narendra Modi sought help for finding remedy to the deadly disease commonly found among tribals in India.
Modi, who has been keenly looking for a remedy to the disease since his days as the chief minister of Gujarat, discussed the issue with Nobel Prize winner for Medicine (2012) S Yamanaka when he visited the Kyoto University.
The PM, on the second day of his tour, raised the issue during his visit to the stem cell research facility and discussed whether Japan could be of help in this regard. Yamanaka is the director of the university.
"I wanted to understand stem cell research because cultural heritage matters as much to me as scientific heritage. I want to integrate both to make India a developed country. It was a good opportunity for me," Modi said.
The PM discussed the possibility of cooperation in finding a treatment for the disease, said External Affairs Ministry spokesman Syed Akbaruddin.
Sources said the Japanese side said it would work with India in jointly finding the treatment.
The sources said Modi, since his days as the Gujarat CM, has been trying to see if any solution could be found to the disease but has been helpless as no cure has been invented yet.
Sickle cell disease is a serious disorder in which the body makes sickle-shaped red blood cells. "sickle-shaped" means that the red blood cells are shaped like a crescent. Normal red blood cells are disc-shaped and look like doughnuts without holes in the center. They move easily through blood vessels. Red blood cells contain an iron-rich protein called hemoglobin. This protein carries oxygen from the lungs to the rest of the body.
Read more from the original source:
In Japan, Modi discusses sickle cell treatment with Nobel laureate
PUBLIC RELEASE DATE:
29-Aug-2014
Contact: Kris Kitto kris@morethanpr.com 303-320-7790 The Bawmann Group
AURORA, Colo. (Sept. 2, 2014) A team of scientists from the University of Colorado School of Medicine has reported the breakthrough discovery of a process to expand production of stem cells used to treat cancer patients. These findings could have implications that extend beyond cancer, including treatments for inborn immunodeficiency and metabolic conditions and autoimmune diseases.
In an article published Aug. 29 in PLOS ONE, researchers from the Charles C. Gates Center for Regenerative Medicine and Stem Cell Biology and Taiga Biotechnologies, Inc. said they have uncovered the keys to the molecular code that appear to regulate the ability of blood stem cells to reproduce and retain their stem-like characteristics.
The team developed protein products that can be directly administered to blood stem cells to encourage them to multiply without permanent genetic modifications.
"Use of stem cells to treat cancer patients who face bone marrow transplants has been a common practice for four decades," said Yosef Refaeli, Ph.D., an associate dermatology professor and one of the study's lead scientists. "The biggest challenge, however, has been finding adequate supplies of stem cells that help patients fight infection after the procedure."
Gates Stem Cell Center Director Dennis Roop, Ph.D., recognized the magnitude of the team's work.
"Researchers have long attempted to increase the number of blood stem cells in a lab," Roop said. "Most of those approaches have been limited by the nature of the resulting cells or the inadequate number of cells produced."
The technology described in the PLOS ONE article has worked with blood stem cells obtained from cord blood, adult bone marrow or peripheral blood from adults.
More:
CU scientists' discovery could lead to new cancer treatment